GSK plc (BCBA:GSK)

Market Cap	168.73T +128.2%
Revenue (ttm)	63.81T +4.1%
Net Income	11.17T +122.0%
EPS	2,711.36 +123.2%
Shares Out	n/a
PE Ratio	15.11
Forward PE	11.82
Dividend	464.72 (2.14%)
Ex-Dividend Date	Nov 14, 2025

Volume	81
Average Volume	1,094
Open	21,680
Previous Close	21,860
Day's Range	21,440 - 21,700
52-Week Range	10,000 - 22,570
Beta	n/a
RSI	69.52
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: GSK

Financial Performance

In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.

Financial numbers in GBP